Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight LossGlobeNewsWire • 03/12/24
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-QGlobeNewsWire • 02/28/24
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight LossGlobeNewsWire • 02/20/24
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)Zacks Investment Research • 02/13/24
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss DrugsGlobeNewsWire • 02/06/24
Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 02/01/24
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 01/31/24
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024GlobeNewsWire • 01/25/24
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight LossGlobeNewsWire • 01/08/24
Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 DrugsGlobeNewsWire • 12/19/23
VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 12/15/23
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further IncreasiGlobeNewsWire • 10/04/23
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)GlobeNewsWire • 09/26/23
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023GlobeNewsWire • 09/20/23
Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast CancerGlobeNewsWire • 09/11/23
Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023GlobeNewsWire • 08/30/23
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023GlobeNewsWire • 08/03/23